SCLX:NSD-Scilex Holding Company (USD)

COMMON STOCK | Drug Manufacturers - General |

Last Closing

USD 0.352

Change

-0.02 (-4.53)%

Market Cap

N/A

Volume

1.27M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-02-10 )

Largest Industry Peers for Drug Manufacturers - General

Symbol Name Price(Change) Market Cap
AZN AstraZeneca PLC ADR

+0.67 (+0.93%)

USD 206.53B
AMGN Amgen Inc

+1.25 (+0.43%)

USD 148.05B
SNY Sanofi ADR

-0.07 (-0.13%)

USD 135.22B
GILD Gilead Sciences Inc

-0.56 (-0.58%)

USD 121.14B
BIIB Biogen Inc

+1.19 (+0.84%)

USD 20.97B
GRFS Grifols SA ADR

-0.14 (-1.97%)

USD 7.13B
AMRN Amarin Corporation PLC

-0.02 (-3.25%)

USD 0.23B
MIRA MIRA Pharmaceuticals, Inc. Com..

+0.02 (+1.74%)

USD 0.02B
SCLXW Scilex Holding Company

-0.03 (-15.00%)

N/A

ETFs Containing SCLX

BTEC 0.00 % 0.42 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - General) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -17.45% 20% F 15% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -17.45% 20% F 15% F
Trailing 12 Months  
Capital Gain -78.67% 10% F 7% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return -78.67% 10% F 7% C-
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -37.80% 10% F 3% F
Dividend Return -37.80% 10% F 3% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 36.07% 30% F 53% F
Risk Adjusted Return -104.80% 10% F 3% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector